Fig 7. Inhibitors of CCHFV entry and transcription inhibit tecVLP signal production.
(A) Neutralization assays of tecVLPs treated with mAbs. Percent inhibition was calculated by comparing the NanoLuc signal strength in SW-13 cells treated with tecVLP and mAbs to signal in cells treated with tecVLPs and a control mAb. (B) Percent inhibition (compared to untreated tecVLP) in SW-13 cells treated with tecVLPs and indicated inhibitors (top panel), and 50% effective concentration (EC50), 50% cytotoxicity concentration (CC50), and selectivity index (SI) for ribavirin and chloroquine in these cells (bottom panel, average of 3 experiments).